ClinicalTrials.gov 临床试验·· 2 天前AI 评分38
Sacituzumab Tirumotecan 联合 PD-1 抑制剂二线治疗晚期食管鳞癌的 II 期单臂临床研究
A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
AI 导读
一项单中心、单臂、前瞻性 II 期临床研究启动,计划入组 30 例一线免疫治疗或免疫联合化疗失败/进展后的晚期转移性食管鳞状细胞癌患者,评估 Sacituzumab Tirumotecan 联合 PD-1 抑制剂的疗效。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov